Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06721-x ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Linlin Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Glutamate Carboxypeptidase II, Lutetium, Antigens, Surface. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: the National High Level Hospital Clinical Research Funding, the Fundamental Research Funds for the Central Universities, Chinese Academy of Medical Science Innovation Fund for Medical Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and radioligand therapy (RLT) of prostate cancer. Two novel PSMA-targeting radionuclide therapy agents, [177Lu]Lu-P17-087, and its albumin binder modified derivative, [177Lu]Lu-P17-088, were evaluated in metastatic castration-resistant prostate cancer (mCRPC) patients. The primary endpoint was dosimetry evaluation, the second endpoint was radiation toxicity assessment (CTCAE 5.0) and PSA response (PCWG3). METHODS: Patients with PSMA-positive tumors were enrolled after [68Ga]Ga-PSMA-11 PET/CT scan. Five mCRPC patients received [177Lu]Lu-P17-087 and four other patients received [177Lu]Lu-P17-088 (1.2 GBq/patient). Multiple whole body planar scintigraphy was performed at 1.5, 4, 24, 48, 72, 120 and 168 h after injection and one SPECT/CT imaging was performed at 24 h post-injection for each patient. Dosimetry evaluation was compared in both patient groups. RESULTS: Patients showed no major clinical side-effects under this low dose treatment. As expected [177Lu]Lu-P17-088 with longer blood circulation (due to its albumin binding) exhibited higher effective doses than [177Lu]Lu-P17-087 (0.151 ± 0.036 vs. 0.056 ± 0.019 mGy/MBq, P = 0.001). Similarly, red marrow received 0.119 ± 0.068 and 0.048 ± 0.020 mGy/MBq, while kidney doses were 0.119 ± 0.068 and 0.046 ± 0.022 mGy/MBq, respectively. [177Lu]Lu-P17-087 demonstrated excellent tumor uptake and faster kinetics; while [177Lu]Lu-P17-088 displayed a slower washout and higher average dose (7.75 ± 4.18 vs. 4.72 ± 2.29 mGy/MBq, P = 0.018). After administration of [177Lu]Lu-P17-087 and [177Lu]Lu-P17-088, 3/5 and 3/4 patients showed reducing PSA values, respectively. CONCLUSION: [177Lu]Lu-P17-088 and [177Lu]Lu-P17-087 displayed different pharmacokinetics but excellent PSMA-targeting dose delivery in mCRPC patients. These two agents are promising RLT agents for personalized treatment of mCRPC. Further studies with increased dose and frequency of RLT are warranted to evaluate the potential therapeutic efficacy. TRIAL REGISTRATION: 177Lu-P17-087/177Lu-P17-088 in Patients with Metastatic Castration-resistant Prostate Cancer (NCT05603559, Registered at 25 October, 2022). URL OF REGISTRY: https://classic. CLINICALTRIALS: gov/ct2/show/NCT05603559 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Ch…
- Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
- College of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China.
- Five Eleven Pharma Inc, Philadelphia, PA, 19104, USA.
- Five Eleven Pharma Inc, Philadelphia, PA, 19104, USA. kunghf@gmail.com.
- Department of Radiology, University of Pennsylvania, 3700 Market Street, Room 305, Philadelphia, PA, 19104, USA. kunghf@gmail.com.
ORCID-Profile: Hank F Kung
Förderung
- the National High Level Hospital Clinical Research Funding
- the Fundamental Research Funds for the Central Universities
- Chinese Academy of Medical Science Innovation Fund for Medical Sciences
- the National Natural Science Foundation of China
Zitieren
APA
Li, L., Wang, J., Wang, G., Wang, R., Jin, W., Zang, J., Sui, H., Jia, C., Jiang, Y., Hong, H., Zhu, L., Alexoff, D., Ploessl, K., Kung, H. F., & Zhu, Z. (2024). Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06721-x
Vancouver
Li L, Wang J, Wang G, Wang R, Jin W, Zang J, et al. Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06721-x
BibTeX
@article{Li2024,
author = {Li, Linlin and Wang, Jiarou and Wang, Guochang and Wang, Rongxi and Jin, Wenbin and Zang, Jie and Sui, Huimin and Jia, Chenhao and Jiang, Yuanyuan and Hong, Haiyan and Zhu, Lin and Alexoff, David and Ploessl, Karl and Kung, Hank F and Zhu, Zhaohui},
title = {Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06721-x}
}
EUVIMED